TY - JOUR
TI - Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: One shared story of two exceptional cases
AU - Ziogas, D.C.
AU - Terpos, E.
AU - Gavriatopoulou, M.
AU - Migkou, M.
AU - Fotiou, D.
AU - Roussou, M.
AU - Kanellias, N.
AU - Tatouli, I.
AU - Eleutherakis-Papaiakovou, E.
AU - Panagiotidis, I.
AU - Ntanasis-Stathopoulos, I.
AU - Kastritis, E.
AU - Dimopoulos, M.A.
JO - Clinical Lymphoma Myeloma and Leukemia
PY - 2018
VL - 59
TODO - 4
SP - 983-987
PB - Taylor and Francis Ltd.
SN - null
TODO - 10.1080/10428194.2017.1361031
TODO - ADP ribosyl cyclase/cyclic ADP ribose hydrolase 1;  amphotericin B lipid complex;  bortezomib;  C reactive protein;  daratumumab;  dexamethasone;  elotuzumab;  lenalidomide;  M protein;  masitinib;  melphalan;  monoclonal antibody;  piperacillin plus tazobactam;  placebo;  recombinant granulocyte colony stimulating factor;  thalidomide;  zoledronic acid;  antineoplastic agent;  antiprotozoal agent;  CD38 protein, human;  membrane protein;  signaling lymphocytic activation molecule;  SLAMF7 protein, human, abdominal radiography;  aged;  amastigote;  autologous stem cell transplantation;  backache;  bone atrophy;  bone marrow biopsy;  cancer combination chemotherapy;  cancer recurrence;  case report;  clinical article;  clinical examination;  comorbidity;  computer assisted tomography;  drug megadose;  febrile neutropenia;  female;  fever;  human;  laboratory test;  Letter;  male;  multiple cycle treatment;  multiple myeloma;  night sweat;  opportunistic infection;  palliative therapy;  pancytopenia;  priority journal;  protein urine level;  radiation dose fractionation;  splenomegaly;  systemic therapy;  treatment response;  urinary excretion;  visceral leishmaniasis;  antagonists and inhibitors;  immunocompromised patient;  immunology;  immunosuppressive treatment;  isolation and purification;  Leishmania donovani;  multiple myeloma;  opportunistic infection;  parasitology;  procedures;  recurrent disease;  visceral leishmaniasis, ADP-ribosyl Cyclase 1;  Aged;  Antineoplastic Combined Chemotherapy Protocols;  Antiprotozoal Agents;  Female;  Humans;  Immunocompromised Host;  Immunosuppression;  Leishmania donovani;  Leishmaniasis, Visceral;  Male;  Membrane Glycoproteins;  Multiple Myeloma;  Opportunistic Infections;  Recurrence;  Signaling Lymphocytic Activation Molecule Family
TODO - null
ER -